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Letters to the Editor
Dear Sir:
The recent article by McKenna et al. (1) on phar-
macokinetics ofvinylidine chloride (VDC) in the rat
has evoked a number ofthoughts. These relate both
to one detail ofdata presentation from the excellent
experimental studies and to the general role of
pharmacokinetics in supporting risk assessment
from high dose studies in mammals.
The detail concerns Figure la (Figure 2 of the
McKenna article) in which they plotted covalent
binding to liver macromolecules versus the
logarithm of the exposure concentration of VDC.
They concluded that the "dose-dependent or satu-
rable character of VDC detoxification is apparent,
indicating an initial deviation from first-order or
linear kinetics at about 50 ppm." A linear-log plot
such as this does not display underlying linear pro-
cesses as a straight line but rather as a curved line
such as they show. The data have been replotted on
a linear scale in Figure lb to illustrate this fact. The
straight line is simply a reference through zero and
the higher points. Quite clearly, the amount of
radioactivity derived from VDC which remains as-
sociated with liver macromolecules is very nearly
proportional to concentration at all concentrations
studied. No simple relationship with nonprotein
sulfhydryl (NPSH) levels is apparent from this data
setalone.
My general comment concerns extrapolation of
irreversible toxicity such as a cancer from an ob-
servable range to a lower range which is of social
concern but statistically inaccessible in an experi-
ment which can be done. A theoretical rationale for
extrapolation could be established by measurement
of a biochemical effect which correlates with car-
cinogenicity in an observable range. One candidate
which should be examined for such a correlation is
covalentbinding to DNA orothermolecules.
It is well established that a foreign chemical may
undergo metabolism to a more toxic form. The
kinetic implications and consequences have been
thoroughly discussed by Gillette (2, 3) and extended
to include numerical simulations involving non-
lineartransient reactions by Gehring(4).
The diagram shows a simplified reaction scheme
following the approach of Gillette (3); much more
complex biochemical networks are possible.
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The parent chemical is represented by A, and the
reactive intermediate is represented by B. The vari-
ous reaction rates are indicated by r as follows: rA
and rB represent the summation ofall processes for
elimination of A and B or chemical conversion to
nontoxic products; rAB is the reaction rate for con-
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FIGURE la, b. Dose-response relationship for (0) hepatic NPSH depletion and (0) covalent binding of 14C-VDC metabolites to liver
protein following inhalation exposure of rats (1).
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FIGUREn 2. Dose-response relationship for hepatic NPSH deple-
tion and covalenty bound 14C-dvity in the liver following
E4C-VC exposure ofrats (1).
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FIGURE 3. Covalent binding of '4C-activity from VC (1) com-
pared with liver angiosarcoma response in rats. The error
bars indicate 2 standard errors (5).
version ofA to the reactive intermediate; rBC repre-
sents the rate ofirreversible reaction ofthe reactive
intermediate with the site oftoxicity, e.g., by cova-
lent binding to RNA, DNA or protein molecules.
Many of the various processes may be enzymati-
cally mediated and kinetically saturable. While a
one-compartment description ofthe body is implied
by the diagram, the various chemical reactions and
excretory processes do not necessarily occur at the
same site. B may be formed in the liver, e.g., and, if
sufficiently stable, could produce toxicity in other
organs.
If all of the processes are linear, the concentra-
tion of the reactive intermediate B (and thus expo-
sure to toxicity) will be proportional to the dose of
A. All processes which are described by Michaelis
Menten kinetics appear linear at sufficiently low
concentration. At higher concentrations, saturation
phenomena produce quite variable results depend-
ing upon the steps where they act. Ifthe pathways
rA orrB leading to nontoxic products and elimination
start to saturate, then the production of C will in-
crease more rapidly thanthe dose. This problem has
been emphasized in the literature (4); however,
there is no reason a priori to assume that pathways
leading- to detoxification will saturate first. If the
pathway rAB leading to B saturates first, then the
production of C may increase less rapidly than
dose.
Covalent binding of radioactivity derived from
vinyl chloride provides a good example of a
biochemical effect which is self-limiting with dose
(1). Figure 2 is a replotting ofthe VC data (Fig. 3 of
the McKenna article) on linear coordinates in the
manner of Figure lb to display this effect more
clearly. It is apparent that covalent binding in-
creases almost linearly up to an exposure concen-
tration of about 200 ppm and then plateaus quite
sharply with relatively little increase from 500 to
5000ppm.
The covalent binding data for VC are plotted
again in Figure 3 alongside the Maltoni data on liver
angiosarcoma in the rat as cited by Guess et al. (5).
The shapes of the curves are strikingly similar.
While this does not prove that covalent binding will
be proportional to tumor incidence at low dose, a
relationship between tumor incidence and VC me-
tabolism is consistent with these data as mentioned
by McKenna. One disturbing consequence of a
dose-response curve such as Figure 3 is that linear
extrapolation from a single high dose will tend to
underestimate the biochemical or pathologic effect
over mostorallofthe range oflowerdoses.
It is not going to be possible to work out the qual-
itative and quantitative aspects of all biochemical
reactions and physiologic processes which will de-
termine dose-response relationships for every
foreign substance in the environment. It may be
possible to simulate mathematically the essential
behavior of rather complex biochemical networks
and make powerful generalizations about their de-
pendence on dose and key kinetic parameters with-
out quantitating or even knowing all details. This
could be a very fruitful area for research which
would involve both considerable mathematical
sophistication as well as careful design of experi-
ments in vitro and in vivo to obtain necessary pa-
rameters.
ROBERT L. DEDRICK
Biomedical Engineering and
Instrumentation Branch, DRS
National Institutes ofHealth
Bethesda, Md. 20014
Environmental Health Perspectives
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Dear Sir:
Dr. Dedrick's perceptive comments regarding our
paper on vinylidene chloride (I) are much ap-
preciated. The discrepancy between the text and
Figure 2 was an oversight in preparation of the
manuscript. For clarification, Figure 1 shows
the relationship between the total metabolism
of VDC and depletion of hepatic glutathione in
rats following a single 6 hr inhalation exposure.
The nonlinear character of VDC metabolism is
more appropriately shown in this figure. Since the
majority of VDC metabolites are represented by
glutathione conjugates the apparent dependence of
VDC metabolism on the availability of GSH is not
surprising. When viewed in the context of the co-
valent binding data shown in Figure lb ofDr. Ded-
rick's letter, it is apparent that detoxification of
VDC is saturable, whereas the production of a
reactive intermediate capable of alkylating tissue
macromolecules is a linear function of VDC expo-
sure concentrations over the range examined. The
data clearly indicate a saturation of detoxification
pathways for VDC prior to an effect on pathways
leading to alkylation ofhepatic macromolecules.
Dr. Dedrick's thoughts on pharmacokinetics and
risk assessment are certainly consistent with the
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efforts of this laboratory over the recent past. The
specific problem of vinyl chloride risk assessment
and the role of pharmacokinetic considerations
therein has been dealt with in detail in two recent
publications from this laboratory (2, 3). Therefore I
will make only one additional comment regarding
the problems of extrapolation of dose-response re-
lationships such as those shown in Figure 3 of Dr.
Dedrick's letter.
Just as extrapolation from a single high dose
tends to underestimate the effect ofinterest at lower
doses, it can also be seen that extrapolation from
two high doses on the upper portion of the curve
would provide agross overestimate ofthe effects at
lower doses. The point to be made is simply that
neither procedure provides an adequate risk as-
sessment. Such considerations are important not
only to the interpretation of hazard evaluation
studies but also their design. In both instances the
primary objective should be a well-defined dose-
response relationship, which includes consid-
erations of metabolic activation, thereby providing
a sounddatabase forrisk assessment.
MICHAEL J. MCKENNA
Toxicology Research Laboratory
Health & Environmental Research
Dow Chemical U.S.A.
Midland, Mich. 48640
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